METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES | Zendy

Suzanne Hendrix | Zendy; N. Ellison | Zendy; Stephanie H. Stanworth | Zendy; L Tierney | Zendy; Frank Mattner | Zendy; Wolfgang Schmidt | Zendy; Bruno Dubois | Zendy; Achim Schneeberger | Zendy

Open Access

METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES

Author(s) -

Suzanne Hendrix,

N. Ellison,

Stephanie H. Stanworth,

L Tierney,

Frank Mattner,

Wolfgang Schmidt,

Bruno Dubois,

Achim Schneeberger

Publication year - 2015

Publication title -

the journal of prevention of alzheimer s disease

Language(s) - English

Resource type - Journals

eISSN - 2426-0266

pISSN - 2274-5807

DOI - 10.14283/jpad.2015.67

Subject(s) - medicine , clinical trial , cognition , neuropsychology , placebo , psychology , psychiatry , pathology , alternative medicine

Optimized scales and composite outcomes have been proposed as a way to more accurately measure Alzheimer's disease related decline. AFFITOPE® AD02, is an amyloid-beta (Aβ)-targeting vaccine to elicit anti-Aβ antibodies. IMM-AD04, commonly known as Alum, originally designated as a control agent, appeared to have disease-modifying activity in a multicenter, parallel group phase II study in early AD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research